Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera.
Barbara MühlemannSamuel H WilksLauren BaraccoMeriem BeklizJuan Manuel CarreñoVictor Max CormanMeredith E Davis-GardnerWanwisa DejnirattisaiMichael S DiamondDaniel C DouekChristian DrostenIsabella EckerleVenkata-Viswanadh EdaraMadison EllisRon A M FouchierMatthew FriemanSucheta GodboleBart HaagmansPeter J HalfmannAmy R HenryTerry C JonesLeah C KatzelnickYoshihiro KawaokaJanine KimpelFlorian KrammerLilin LaiChang LiuSabrina LusvarghiBenjamin MeyerJuthathip MongkolsapayaDavid C MontefioriAnna MykytynAntonia NetzlSimon PollettAnnika RösslerGavin R ScreatonXiaoying ShenAlex SigalViviana SimonRahul SubramanianPiyada SupasaMehul S SutharSina TüreliWei WangCarol D WeissDerek J SmithPublished in: bioRxiv : the preprint server for biology (2023)
The antigenic evolution of SARS-CoV-2 requires ongoing monitoring to judge the immune escape of newly arising variants. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal sera. We compared 18 datasets generated using human, hamster, and mouse sera, and six different neutralization assays. Titer magnitude was lowest in human, intermediate in hamster, and highest in mouse sera. Fold change, immunodominance patterns and antigenic maps were similar among sera. Most assays yielded similar results, except for differences in fold change in cytopathic effect assays. Not enough data was available for conclusively judging mouse sera, but hamster sera were a consistent surrogate for human first-infection sera.